Planning for posttrial access to antiretroviral treatment for research participants in developing countries

American Journal of Public Health

Volumn 99, Issue 9, 2009, Pages 1556-1562

  Shah, Seema ^a   Elmer, Stacey ^a   Grady, Christine ^a  

^a Department of Bioethics ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL RESEARCH; CONTROLLED STUDY; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; INFORMED CONSENT; MEDICAL DOCUMENTATION; PRACTICE GUIDELINE; TREATMENT PLANNING;

ADULT; AFRICA; ANTI-RETROVIRAL AGENTS; ASIA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CONTINUITY OF PATIENT CARE; COSTS AND COST ANALYSIS; DEVELOPING COUNTRIES; GUIDELINE ADHERENCE; GUIDELINES AS TOPIC; HAITI; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); RESEARCH SUBJECTS; SOUTH AMERICA; UNITED STATES; YOUNG ADULT;

EID: 69049092741     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2008.157982     Document Type: Article

References (15)

1. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. 2002 revision. Available at: http://www.wma.net/e/index.htm. Accessed July 16, 2008.
2. National Bioethics Advisory Commission. Ethical and policy issues in international research: clinical trials in developing countries. Published April 1, 2001. Available at: http://bioethics.georgetown.edu/nbac/clinical/Vol1.pdf. Accessed March 24, 2009.
3. Nuffield Council of Bioethics. The ethics of research related to health care in developing countries. 2004. Available at: http://www.nuffieldbioethics. org/go/ourwork/developingcountries/publication-309.html. Accessed July 16, 2008.
4. National Consensus Conference on Bioethics and Health Research in Uganda. Guidelines for the Conduct of Health Research Involving Human Subjects in Uganda. Kampala, Uganda: Uganda National Council of Science and Technology; 1998.
5. National Health Council of Brazil. Resolution No. 196/96 on research involving human subjects. 1996. Available at: http://coralx.ufsm.br/prpgp/pdf/ resolucao-196-en.pdf. Accessed March 24, 2009.
6. Clinical Trial Working Group of the South Africa Department of Health. Guidelines for good practice in the conduct of clinical trials in human participants in South Africa. Available at: http://www.doh.gov.za/docs/policy/ trials/trials-contents.html. Accessed July 16, 2008.
7. Indian Council of Medical Research. Ethical guidelines for biomedical research on human participants. Available at: http://icmr.nic.in/ethical- guidelines.pdf. Accessed July 17, 2008.
8. National Institutes of Health. Estimates of funding for various research, condition, and disease categories. 2008. Available at: http://www.nih.gov/news/ fundingresearchareas.htm. Accessed July 17, 2008.
9. National Institutes of Health. Guidance for addressing the provision of antiretroviral treatment for trial participants following their completion of NIH-funded HIV antiretroviral treatment trials in developing countries. 2005. Available at: http://grants.nih.gov/grants/policy/antiretroviral/guidance.doc. Accessed July 16, 2008.
10. National Institutes of Health. Division of AIDS. DAIDS broadcast memos and policies. Important update on language to be added to the DAIDS sample informed consent templates for studies providing drug(s) and/or agent(s). 2005. Available at: http://rcc.tech-res.com/memos.htm. Accessed July 16, 2008.
11. Ethical considerations in HIV preventive vaccine research. 2000. Available at: http://data.unaids.org/Publications/IRC-pub01/JC072-EthicalCons- en.pdf. Accessed July 16, 2008.
12. London AJ. Justice and the human development approach to international research. Hastings Cent Rep. 2005;35:24-37.
13. Tarantola D, Macklin R, Reed ZH, et al. Ethical considerations related to the provision of care and treatment in vaccine trials. Vaccine. 2007;25:4863-4874.
14. Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Sathapatayavongs B. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen. Int J STD AIDS. 2007;18(12):832-834.
15. Phillips AN, Carr A, Neuhaus J. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008;13(2):177-187.